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Abstract
Aim: To establish the prevalence, management and response 
to treatment of interstitial lung disease (ILD) in Malta. 
Methodology: The personal files of 102 living and 26 deceased 
patients with ILD under the care of 4 respiratory physicians were 
reviewed retrospectively. The investigations utilised for reaching 
the diagnosis, patient management and response to treatment 
were analysed. 
Results: The prevalence of ILD was estimated at 24.9 per 
100,000 population. Pulmonary function tests were performed 
at least once in 109 patients (n=128, 85%), and pletysmography 
and exercise oximetry in 36 patients (n=128, 28%). A chest x-ray 
(CXR) was performed in 120 patients (n=128, 93.7%), of which 
8 (n=120, 6.66%) were normal, a computed tomography scan of 
the thorax in 113 patients (n=128, 88.3%), all of which showed 
fibrotic changes and a DTPA scan in 17 patients (n=128, 13.3%). 
Regarding more invasive investigations, bronchoalveolar lavage 
was performed in 10 patients (n=128, 7.8%), open lung biopsy in 
4 patients (n=128, 3.1 %), video-assisted thoracoscopic surgery in 4 
patients (n=128, 3.1%) and transbronchial lung biopsy in 7 patients 
(n=128, 5.5%). Corticosteroids were the most common drugs 
prescribed in 64 patients (n=128, 50%) followed by azathioprine 
in 23 patients (n=128, 18%) and cyclophosphamide in 3 patients 
(n=128, 2.3%). There was a definite worsening in lung function 
associated with increasing age. There was no standardisation of 
follow up for these patients. 
Conclusion: The method of diagnosis, management and follow 
up of patients with ILD locally requires improvement to optimise 
standards of care and hence compare with proposed international 
guidelines. 
Introduction
Interstitial lung disease (ILD) represents a heterogeneous 
group of distinct parenchymal pulmonary disorders with 
variable degrees of inflammation and fibrosis, based on 
similarities of various clinical features. However, there are 
significant differences in aetiology, radiological and histological 
features, and also in the clinical course, prognosis, treatment 
and response to treatment. ILD has always posed a challenge 
to respiratory physicians with regards to the differential roles 
of the main diagnostic tools and methods of assessing disease 
progression. 
The delivery of medical treatment according to guidelines is 
increasingly viewed as the preferred model of clinical practice. A 
major difficulty in developing guidelines in ILD is the necessity 
of incorporating recommendations relating to a heterogenous 
group of rare disorders. While as a group the various forms of 
ILD form a significant proportion of respiratory morbidity in 
the community, individually they are uncommon leading to a 
lack of expertise in their diagnosis and management. The failure 
to adopt uniform disease definitions and treatment protocols, 
have made the interpretation of results confusing and therefore 
incorporation of the evidence into guidelines difficult.l An 
international study reveals that in the United States, the large 
majority (75%) of patients suffering from nonspecific ILD had 
no evidence of having undergone diagnostic testing and when 
persons with ILD are thoroughly evaluated at referral centres, 
a substantial proportion (more than 50%) are found to have 
idiopathic pulmonary fibrosis (lPF).2 
To date, no data are available locally. The purpose of this 
initiative is to evaluate the prevalence, method of diagnosis, 
management and response to treatment of such patients locally 
and compare these to proposed international guidelines. 
Methodogy
The medical records of 102 living and 26 deceased patients, 
suffering from ILD under the care of respiratory physicians in 
Malta, were reviewed between February and September 2009. 
Approval was obtained from the Head of the Department 
of Medicine, all consultant respiratory physicians and the 
data protection officer at Mater Dei Hospital. An audit form 
was compiled. Demographic data, bird exposure, smoking 
history, drug history, symptoms and signs at presentation, and 
investigations utilised were collected. The patients' management 
was reviewed. Response to treatment was analysed from the 
trend in consecutive spirometry readings. Data were transferred 
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from the audit forms to a Microsoft Excel sheet and results 
were compiled. 
Results 
A total of 128 patients were included with 65 (50.8%) males 
and 63 (49.2%) females, 102 (79.7%) of who were alive and 
26 (20.3%) deceased at the time of auditing. The mean age at 
presentation was 62 years and ranged between 22 and 83 years. 
The mean age between diagnosis and review of the data in the 
live patients was 4.4 years and ranged between 1 and 18 years. At 
the time of diagnosis there were 14 patients (n=128, 10.9%) who 
were current smokers, 63 (n=128, 49.2%) who never smoked 
and 47 (n=128, 36.7%) ex-smokers. 
The prevalence of patients diagnosed with ILD was estimated 
at 24.9 per 100,000 population. The patients were grouped into 
the distinct forms of ILD according to the information available 
in the clinical notes. 
Diagnostic methods utilised included spirometry and flow 
volume loops, radiological and histological investigations, and 
serology. PFTs were never performed in 15 patients (n=128, 
11.9%) and performed at least once in 113 patients (n=128, 
89.7%). Pletysmography and exercise oximetry were performed 
in 36 patients (n=128, 28%). A CXR was performed in 120 
patients (n=128, 93.7%) of which, only 8 (n=128, 6.2%) showed 
no fibrotic changes and a CT thorax in 113 patients (n=128, 
88.3%) all of which showed fibrotic changes. A bronchoalveolar 
lavage was performed in 10 patients (n=128, 7.8%), an open lung 
biopsy in 4 patients (n=128, 3.1%), VATS in 4 patients (n=128, 
3.1%) and a transbronchial lung biopsy in 7 patients (n=128, 
5.5%). A DTPA scan was performed in 17 patients (n=128, 
13.3%). DTPA scan results included 12 (n=17, 71 %) having 
increased alveolar permeability or active alveolitis and the 
remaining 5 (n=17, 29%) being normal. Serology screening was 
reviewed. Serum anti-nuclear antibodies (ANA), antineutrophil 
cytoplasmic antibodies (ANCA) and rheumatoid factor (RF) 
levels were performed in 57%, 27.3% and 57.8% respectively and 
were positive in 18 patients (n=73, 25%), 2 patients (n=35, 5.7%) 
and 16 patients (n=74, 21.6%) respectively. Serum angiotensin 
converting enzyme (ACE) levels were significantly raised in 
4 patients (n=31, 13%). Avian precipitins were positive in 34 
patients (n=65, 52%). Of these, only 18 (n=34, 52.9%) had a 
history of prolonged avian exposure. 
Corticosteroids were prescribed in 64 patients (n=128, 50%) 
at some stage of the disease, with a large proportion in the less 
than 60 age group, followed by azathioprine in 23 patients 
(n=128, 18%) and cyclophosphamide in 3 patients (n=128, 
2.3%). Of the patients who were prescribed azathioprine, 87% 
of them were also prescribed corticosteroids. Three patients 
Table 1: Causes of death obtained from 
available death certificate
Cause
Number 
of patients 
Percentage 
number of 
patients
Respiratory failure  
secondary to pulmonary 
fibrosis
10 38.5 %
Chest infection 3 11.5
Lung malignancy 3 11.5
Extra-pulmonary 2 7.8
Unavailable death 
certificate
8 30.8
Figure 1: The number of patients per heterogenous form 
of pulmonary fibrosis diagnosed locally
Figure 3: Treatment prescribed for the heterogenous 
types of IPF
Figure 2: Results of the different tissue samples obtained 
and their contribution to differentiating the heterogenous 
forms of ILD
 Not diagnostic
 Diagnostic
IlD: Interstitial lung disease
BX: Biopsy
BAL: Bronchoalveolar lavage
VATS - Video-assisted thoracoscopic surgery
LN - Lymph node
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(n=l28, 2.3%) were on amiodarone at the time of auditing. Four 
patients were diagnosed with amiodarone-¬induced ILD. Only 
1 patient had methotrexate-induced ILD. 
Of the patients treated with azathioprine (n=23), there were 
21% who showed improvement in pulmonary function, 27% with 
worsening and 21% who were stable. The rest of the patients 
did not have sufficient spirometries performed to analyse the 
trend. Patients treated with cyclophosphamide were too small 
a number to analyse. 
Analysis of the results of the deceased patients showed a mean 
time from diagnosis to death of 5.57 years which ranged between 1 
and 12 years. Twelve of these patients had received corticosteroids 
only, 2 received solely azathioprine, 6 received both and the rest, 
6 patients, were never prescribed any form of treatment for ILD. 
 
Discussion 
The prevalence of ILD calculated may be an underestimate 
since patients included in this audit were only those under the 
care of respiratory physicians. However, this is likely to be a 
good estimate as there is a tendency for other physicians to 
refer such patients to a respiratory specialist. Patients with 
pulmonary fibrosis secondary to connective tissue diseases or 
those under the care of other physicians were not included. 
Despite the guidelines for diagnosis with clearly described 
Figure 4: Percentages of pulmonary function trends in 
patients treated with steroids as opposed to those who 
were not
 Steroids
 No steroids
Figure 5: Percentage of patients and their lung function 
trend in association with age
criteria, ILD remains a diagnosis of exclusion requiring 
extensive investigation, which is seldom possible. Hence, it is 
not possible to precisely estimate the incidence and prevalence 
rates of ILD.3 Unfortunately, the worldwide prevalence of 
fibrotic lung diseases is difficult to determine because of lack 
of studies performed.4 Having the correct specific diagnosis 
helps clinicians have a clear plan of management of the disease. 
Since the diagnosis of the specific type of ILD was not made in 
54 patients (42.2%), optimal management was limited. Age 
and late presentation were factors that contributed to a lack of 
diagnosis. Poor general health precluded invasive investigation. 
Some patients with minimal symptoms and mild disease were 
amongst those who were not investigated further. Others were 
also lost to follow up. 
As the majority of ILDs involve varying degree of 
inflammatory or fibrotic infiltration of alveolar walls, they share 
common restrictive physiological abnormality on pulmonary 
function testing.5 Pulmonary function tests (PFTs) are cheap, 
non-invasive and contribute to quantifying disease severity, 
monitor disease progression and help identify variables most 
strongly predictive of mortality. Unfortunately, studies of these 
important aspects of routine management are largely confined 
to lPF. Therefore, it is advised that all patients with ILD should 
have a resting spirometric and gas transfer measurement at 
presentation, which together provides a reasonable measure of 
disease severity. Possibilities as to why PFTs were not performed 
include uncooperative patients, contra-indications to PFTs, 
and possibly lack of insight of the importance of such a tool. 
According to graph 5, there is a definite worsening in lung 
function associated with increasing age, as would be expected in 
a chronic condition. Progression of the disease was followed up 
by performing regular spirometries in some, especially those who 
were receiving treatment, and these patients were also followed 
up more regularly at the out-patients clinics. However, there was 
no standardisation as to the regular performance of pulmonary 
function tests (PFTs), exercise oximetry and pletysmography. 
Change in forced vital capacity (FVC) has emerged as the serial 
lung function measurement most consistently predictive of 
mortality. A change in FVC of only 10% is needed to identify 
a true change in disease severity.2 Unfortunately, the carbon 
monoxide transfer factor (TLCO) could not be measured as it 
was not available locally until very recently. 
Recent literature suggests that exercise testing provides 
diagnostic and prognostic value in ILD. When normal, it is 
useful in excluding clinically significant diffuse lung disease. 
Exercise-induced hypoxia may be an early indicator of disease 
before the development of pulmonary function abnormalities. 
Desaturation during the 6 minute walk test at presentation is 
a stronger prognostic determinant in IPF than resting lung 
function, but probably adds little in assessing the severity 
of ILD owing to the absence of a "gold standard" to quantify 
disease severity.6,7 Despite it being a cheap, non-invasive tool, 
it was not often requested locally. Possible explanations include 
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immobility or lack of physician awareness of its importance. 
Despite the limitations of chest radiography and the paucity 
of published evidence to support its use, it is widely used for 
patients with ILD. Locally, a CXR performed at presentation, 
aided in confirming the diagnosis in most cases. In conjunction 
with clinical and laboratory findings, it may allow a confident 
diagnosis to be made. It is also useful, but often non-specific 
for detecting secondary pulmonary complications. However, 
PFTs usually reflect the severity of disease more accurately 
than chest radiography.6 High resolution computed tomography 
(HRCT) scanning is significantly superior to CXR in identifying 
and determining the correct diagnosis of ILD. With its greater 
ability to visualise fine detail within the lung, HRCT scanning 
has replaced conventional chest radiography as the preferred 
imaging method for ILDs. It has been found useful in the 
evaluation of ILDs in the following areas: identification of 
the presence of disease, evaluation of the extent of disease, 
characterisation disease patterns, narrowing the differential 
diagnosis, as a guide to the site of biopsy, and assessing 
the clinical course of the disease and response to therapy.8 
Investigators have identified the key features that allow HRCT 
scanning to provide highly disease-specific information leading 
to a confident, definite diagnosis with a sensitive means of 
staging disease severity. PFTs complement HRCT, helping 
the clinician to discount trivial disease on HRCT scans but 
to recognise, especially with estimation of gas transfer, that 
HRCT may underestimate widespread and clinically important 
pulmonary infiltration.6 Most patients with clinically significant 
ILD have an abnormal HRCT scan but a normal HRCT scan 
does not exclude it.6,8 Radiologists interpreting HRCT scans 
should have experience in the technique and be responsible 
for quality assurance. Locally, none of the CT scan reports 
gave a diagnosis of the ILD type. Most reports were vague and 
non¬specific. A proportion of images were difficult to interpret 
in view of movement artefacts. One must also consider that 
patients' dyspnoea will interfere with sufficient co-operation 
to carry out the study. Bronchoalveolar lavage (BAL) is a 
well-tolerated procedure and plays an important role in the 
diagnostic evaluation of new onset ILDs in patients with 
clinical features and HRCT appearances not typical of IPF. The 
decision to perform bronchoscopy and BAL should be guided 
by clinical presentation, the patient's functional status as well 
as technical expertise, both in performing the procedure and 
in interpreting the BAL cellular component. In some ILDs 
such as hypersensitivity pneumonitis, positive findings by BAL 
analysis may be sufficient to formulate a specific diagnosis, thus 
avoiding the need for more invasive procedures.7 Locally, BAL, 
when performed, did not contribute to differentiating the types 
of ILD, but aided in exclusion of malignant conditions such as 
bronchoalveolar cell carcinoma. 
In the last century, it was widely accepted that the diagnostic 
"gold standard" for ILD was a histological diagnosis made 
on a surgical biopsy. However, the limitations of diagnoses 
relying solely on histology are increasingly recognised. In 
many patients, the disease is too advanced or co-morbidity 
too severe to allow a surgical biopsy to be performed. The 
procedure is highly unattractive to patients and physicians 
alike. Also, there is significant interobserver variation in 
histological reports and the problem of "sampling error."6 Its 
use in the evaluation of suspected IPF was discussed by the 
joint ATSIERS/JRS taskforce in 2009. Based on the additional 
morbidity of transbronchial lung biopsy in these patients and a 
low diagnostic specificity, it has not been recommended. Despite 
this, diagnoses made from such investigations were varied 
and included bronchiolitis obliterans organising pneumonia 
(BOOP), desquamative interstitial pneumonia, extrinsic allergic 
alveolitis (EAA), sarcoidosis and usual interstitial pneumonia, 
hence the possibility of targeting treatment. Multiple multilobe 
lung biopsies are easier by video-assisted thoracoscopic sugery 
(VATS) than by open lung biopsy. VATS is also associated with 
less early postoperative pain than open lung biopsy. Pulmonary 
complications are well recognised in connective tissue 
diseases and ILD has been described as the sole initial clinical 
manifestation of connective tissue diseases. The ATSIERS/
JRS taskforce in 2009 recommends that serological testing for 
connective tissue diseases should be performed in the evaluation 
of IPF even in the absence of signs or symptoms of connective 
tissue diseases. These serological tests include RF, anti-cyclic 
citrullinated peptide, and ANA titre and pattern. The routine 
use of other serological tests is of unclear benefit.9 
With regard to IPF in particular, the last 3 years have 
seen more studies of treatment than in the previous history 
of the specialty, yet there is no universally accepted "best 
current treatment."6 However, targeting treatment to the 
correct diagnosis is advisable. A larger proportion of patients 
showed stable or improved lung function when treated with 
corticosteroids compared to those who were not, indicating the 
positive response of some ILDs to corticosteroids. However, the 
larger percentage of patients who had worsening pulmonary 
function despite corticosteroids could reflect that patients have 
more extensive or more rapidly progressive disease. All patients 
who were receiving amiodarone at the time of auditing had all 
been diagnosed with a differential type of ILD-EAA, BOOP 
and asbestosis. There was a large variation in the amount 
of information documented on follow up visits for different 
patients. Important symptoms such as exertional dyspnoea and 
exercise tolerance were often not mentioned, hence making it 
difficult to monitor symptomatic improvement or deterioration 
over time. A standard template for symptom scoring could be 
filled by patients while waiting at the out-patient clinic and any 
worsening could alert the physician to the need of a change in 
management. 
The fact that 77% of deceased patients had received drugs 
at some point since diagnosis may be explained by the fact that 
their deterioration necessitated treatment to slow down disease 
progression. 
The reported frequency of lung cancer in the setting of 
diffuse pulmonary fibrosis varies greatly, depending on the 
Malta Medical Journal    Volume 24   Issue 02   2012 15
country of origin and the type of study. Frequency ranges from 
4.8% in the United States to 48.2% in Japan. The molecular and 
genetic mechanisms governing the development of lung cancer 
require additional study.10 
Conclusion 
Improving our knowledge on disease classification, 
understanding pathogenesis of the disease and updating 
ourselves with novel therapies are important in order to achieve 
an accurate diagnosis and hence plan further management. 
We have concluded that the diagnosis and management of 
pulmonary fibrosis locally requires improvement m order to 
compare with international guidelines. The adoption of clinical 
guidelines that utilise standardised disease definitions, and 
which target the investigation and management, would help to 
standardise care and hopefully improve patient outcomes. We 
strongly recommended that a multidisciplinary team consisting 
of respiratory physicians, radiologists and pathologists should 
be used in the evaluation of ILD. Introducing measurement of 
the carbon monoxide transfer factor locally promises to be an 
important tool to optimise monitoring of these patients. 
Limitations of the audit 
The CT scan reports were often a strong limiting factor 
since the heterogeneous types of pulmonary fibrosis could 
not be distinguished from the report. Haphazard follow up of 
these patients and irregular use of pulmonary function tests 
made it difficult to assess the rate of progression of the disease. 
Documentation was at times incomplete. A proportion of 
patients did not have a working diagnosis, making follow-up and 
management more difficult for different physicians reviewing 
these patients. 
Further studies 
We suggest reviewing the management and progression 
of patients suffering from pulmonary fibrosis secondary to 
connective tissue disorders. These patients are more likely to 
be treated with corticosteroids and other immunosuppressive 
agents. 
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